

Ref: P24-0246/JW/so
25 March 2024



Ms C Glancy
Programme Officer
Banks Solutions
80 Lavinia Way
East Preston
West Sussex
BN16 1DD

Vail Williams LLP
Goldvale House
27-41 Church Street West
WOKING
Surrey
GU21 6DH

Tel 01483 446800
vailwilliams.com

By email only: bankssolutionsuk@gmail.co.uk

Dear Ms Glancy

Representations to the Elmbridge Local Plan 2037

Matters, Issues and Questions, Stage 2

On behalf of Haleon

Site: St George's Avenue, Weybridge, KT13 0DE (Site Allocation Reference: WEY33)

User ID 41249729

Vail Williams LLP have been instructed by Haleon to make representation to the Elmbridge Local Plan 2037. These comments respond to the Stage 2 MIQs and supplement previous submissions by Haleon (formally part of GlaxoSmithKline).

Haleon is a world-leading consumer health company with a clear purpose to deliver better everyday health with humanity. Their leading brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. Haleon are currently progressing a proposal to relocate from their St. Georges site to the Heights. Building on GSK's previous presence in Weybridge, Haleon's new facility will be co-located alongside other multi-national corporations and will further cement the area's burgeoning status as a high-tech centre of excellence for innovation.

Planning permission was granted in August 2022 (ref: 2021/4257) and the permission has been implemented. Subsequently, a review undertaken by Haleon identified the need for amendments to accommodate their specific needs and a new planning application was submitted to Elmbridge Borough Council on 30 November 2023, reference: 2023/3281. This application is currently pending and demonstrates their continued commitment to Weybridge.

- **Please find enclosed response to MIQ Matter 9 – Site Allocations.**

LISTEN

CARE

VWValues



INNOVATE

LEAD



Whilst we have not made direct representations in response to the MIQs on Matter 4 (Housing Requirement), Matter 5 (Housing Delivery), or Matter 8 (Employment), they are all interlinked with the Haleon site (WEY33) and referenced with the Regulation 19 Representations. We will monitor these aspects and can provide further confirmation regarding Haleon if these Matters raise any queries that effect WEY33 and Haleon.

If there are any queries, in relation to site allocation WEY33 or the relocation of Haleon to the Heights, we would gladly provide further clarification.

Yours sincerely



James Williams BA (Hons) MA MRTPI
Associate
For and on behalf of Vail Williams LLP
Mob: 07887 627 931
Email: jwilliams@vailwilliams.com

LISTEN

CARE



INNOVATE

LEAD